Dr. Eytan Abraham heads the Resilience Cell, Gene, and Nucleic Acids Franchise Businesses, with a focus on partnering with leading Pharma, Biotech, and Clinical Centers to deliver best in class process development as well as clinical and commercial biomanufacturing.
Prior to Resilience, Eytan established and led the Lonza heading Personalized Medicine Business Unit, as well as was head of Lonza’s Cell and Gene Therapy R&D.
Dr. Abraham has over 15 years of experience in the Cell and Gene space focusing on R&D, CMC, and Commercial development. He is the author of over 20 publications and inventor on 12 therapeutic and biomanufacturing patents.
He holds a Ph.D. in developmental and molecular biology from the University of Maryland Biotechnology Institute, and a post-doctorate in cell therapy and tissue engineering from the Harvard-MIT Biomedical Engineering Center and Harvard Medical School